Challenges that remain in treating older patients with ALL

Caner Saygin, MD, University of Chicago, Chicago, IL, addresses challenges in treating older patients with acute lymphoblastic leukemia (ALL). Older patients exhibit distinct disease biology, often characterized by a higher prevalence of higher-risk genetic mutations. While those with Philadelphia-positive (Ph+) ALL benefit from tyrosine kinase inhibitors (TKi) with a favorable prognosis, there remains a need for advancements in treating older patients with other subtypes of high-risk disease. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.